Drugs / ASK120067
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT05306132 | Aug 2022 → Dec 2026 expected | neoplasm | Jiangsu Aosaikang Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1 | NCT04360915 | Dec 2019 | — | Jiangsu Aosaikang Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 31 trial · 1 met primary | ||||||
| Phase 3 | NCT04143607 | Jul 2019 → Mar 2024 overdue | — | Jiangsu Aosaikang Pharmaceutical Co., Ltd. | Active not recruiting | Met primary |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ASK120067 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04143607 ↗ |
| Route | Oral | “ASK120067 (80 mg orally twice daily)” NCT04143607 ↗ |